

OHIO STATE MEDICAL ASSOCIATION HOUSE OF DELEGATES

Resolution No. 23 – 2025

Introduced by: Albert L Hsu, MD

Subject: Registry for Potential Side Effects of GIP & GLP-1 Medications

Referred to: Resolutions Committee No. 1

WHEREAS, gastric inhibitory polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) medications continue to be heavily advertised and touted as some kind of miracle drug for weight loss—besides their main indication as treatment for diabetes, there are limited studies on the potential side-effects—especially those involving the senior (65 years and older) population, such as muscle loss and bone density loss; and

WHEREAS, the costs of these medications continue to be high and they can potentially cost the healthcare system a lot of money over the long run; and

WHEREAS, there are no clear guidelines of how long patients should be taking these medications, which are meant to be long-term and potentially life-long weight management medications, and whether the weight loss will be maintained if patients ever want to come off them; and

WHEREAS, there are no long-term studies of the potential side effects of these medications while many side effects have been seen; and

WHEREAS, there are no current recommendations to better safeguard patients taking these medications and patients are not required to be monitored by qualified health professionals, such as obesity specialists, endocrinologists, or gastroenterologists, while taking these medications; and

WHEREAS, there is no data to support using GLP-1 receptor agonists during pregnancy; and therefore be it

RESOLVED, that our AMA support and call for a registry of GIP and GLP-1 receptor agonists' side effects, as well as potential impacts on pregnancy (Directive to Take Action).

Fiscal Note: \$500+ (Sponsor)
\$ \$25,000- \$500,000 (Staff)

1. Seino, Y, Fukushima, M., & Tabe, D. (2010). GIP and GLP-1, the two incretin hormones: Similarities and differences. *Journal of Diabetes Investigation*. 1:12, 8-23. <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4020673/>
2. FDA-approved label for Ozempic (Semaglutide): https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/209637s020s021lbl.pdf
3. FDA-approved label for Zepbound (Tirzepatide): https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/217806s000lbl.pdf
4. Cubanski, J, Neuman, T. & Sroczynski. (2024). A new use for Wegovy open the door to Medicare coverage for millions of people with obesity. *Kaiser Family Foundation Issue Brief*. <https://www.kff.org/medicare/issue-brief/a-new-use-for-wegovy-opens-the-door-to-medicare-coverage-for-millions-of-people-with-obesity/>
5. Sodhi, M, Rezaeianzadeh, R., & Kezouh, A. (2023). Risk of gastrointestinal adverse events associated with glucagon-like peptide-1 receptor agonists for weight loss. *JAMA*. 330(18): 1795-1797. <https://jamanetwork.com/journals/jama/fullarticle/2810542>
6. Joshi, G.P, Abdelmalak, B.B., Weigel, W.A., Soriano, S.G., Harbell, M.W., Kuo, C.I., Stricker, P.A., Domino, K.B. (2023). American Society of Anesthesiologists consensus-based guidance on perioperative management of patients (adults and children) on glucagon-like peptide-1 (GLP-1) receptor agonists. *American Society of Anesthesiologists Press Release*: June 29, 2023. <https://www.asahq.org/about-asa/newsroom/news-releases/2023/06/american-society-of-anesthesiologists-consensus-based-guidance-on-preoperative>
7. Niewijk, G. (2024). Research shows GLP-1 receptor agonist drugs are effective but come with complex concerns. *University of Chicago Medicine Press Release*: May 30, 2024. <https://www.uchicagomedicine.org/forefront/research-and-discoveries-articles/2024/may/research-on-glp-1-drugs>
8. Cassata, C. (2023). Ozempic can cause major loss of muscle mass and reduce bone density. *Healthline*: May 2, 2023. <https://www.healthline.com/health-news/ozempic-muscle-mass-loss>
9. Daniel, K. (2024). What older adults need to know before taking a GLP-1 like Ozempic. *Everyday Health*: May 17, 2024. <https://www.everydayhealth.com/obesity/what-older-adults-need-to-know-before-taking-a-glp-1-like-ozempic/>